Arnold M.  Baskies net worth and biography

Arnold Baskies Biography and Net Worth

Director of Anixa Biosciences
Dr. Arnold Baskies M.D. serves as Independent Director of the Company. Dr. Baskies is a surgical oncologist at Virtua Health Systems in southern New Jersey, where he specializes in surgical oncology and general surgery. He trained at Boston University Medical Center and the Surgery Branch of the National Cancer Institute where his early research involved immunotherapy. He has extensive experience in all facets of general surgical problems, with special interests in the treatment of breast cancer, gastrointestinal cancers, thyroid cancer, melanoma, and parathyroid disease, and is a co-investigator in several national studies dealing with breast cancer prevention. He served as chairman of the New Jersey Governor’s Task Force on Early Detection, Prevention and Treatment of Cancer, having created and chaired the cancer control plan for the state from 2000-2016, and is a member of numerous societies, including the Society of Surgical Oncology, the American Society of Breast Surgeons, and the American College of Surgeons. Dr. Baskies has been involved with the American Cancer Society for 40 years. He was awarded the Society’s Silver Chalice Award in 1998 and the Society’s St. George National Award in 2009. He has held leadership positions at many levels of the organization, including service as the first board scientific officer for the American Cancer Society Board of Directors in 2015, and was the chief medical officer and Chairman of the Board of Directors of the former Eastern Division of the American Cancer Society. In 2017, he served as the Chairman of the Board of the American Cancer Society. He presently serves as immediate past chair of the American Cancer Society Board of Directors, having served as a member of the Board of Directors since 2013. He currently chairs the Global Cancer Control Advisory Council for the society. He received a medical degree from Boston University School of Medicine in 1975 and a bachelor of arts degree from Boston University College of Liberal Arts in 1971.

What is Arnold M. Baskies' net worth?

The estimated net worth of Arnold M. Baskies is at least $349,800.00 as of March 15th, 2024. Dr. Baskies owns 110,000 shares of Anixa Biosciences stock worth more than $349,800 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Baskies may own. Learn More about Arnold M. Baskies' net worth.

How do I contact Arnold M. Baskies?

The corporate mailing address for Dr. Baskies and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]. Learn More on Arnold M. Baskies' contact information.

Has Arnold M. Baskies been buying or selling shares of Anixa Biosciences?

Arnold M. Baskies has not been actively trading shares of Anixa Biosciences over the course of the past ninety days. Most recently, on Friday, March 15th, Arnold M. Baskies bought 10,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.63 per share, with a total value of $36,300.00. Following the completion of the transaction, the director now directly owns 110,000 shares of the company's stock, valued at $399,300. Learn More on Arnold M. Baskies' trading history.

Who are Anixa Biosciences' active insiders?

Anixa Biosciences' insider roster includes Arnold Baskies (Director), Emily Gottschalk (Director), Amit Kumar (CEO), and Lewis Titterton, Jr. (Director). Learn More on Anixa Biosciences' active insiders.

Are insiders buying or selling shares of Anixa Biosciences?

In the last year, Anixa Biosciences insiders bought shares 4 times. They purchased a total of 60,509 shares worth more than $202,149.52. In the last year, insiders at the sold shares 1 times. They sold a total of 11,800 shares worth more than $42,126.00. The most recent insider tranaction occured on April, 9th when Director Lewis H Titterton Jr bought 15,009 shares worth more than $49,229.52. Insiders at Anixa Biosciences own 22.6% of the company. Learn More about insider trades at Anixa Biosciences.

Information on this page was last updated on 4/9/2024.

Arnold M. Baskies Insider Trading History at Anixa Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2024Buy10,000$3.63$36,300.00110,000View SEC Filing Icon  
7/23/2021Buy19,000$4.33$82,270.00View SEC Filing Icon  
3/25/2021Buy10,000$4.80$48,000.0015,600View SEC Filing Icon  
1/17/2020Buy10,000$3.74$37,400.0021,000View SEC Filing Icon  
4/26/2019Buy10,000$4.28$42,800.00View SEC Filing Icon  
See Full Table

Arnold M. Baskies Buying and Selling Activity at Anixa Biosciences

This chart shows Arnold M Baskies's buying and selling at Anixa Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anixa Biosciences Company Overview

Anixa Biosciences logo
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More

Today's Range

Now: $3.18
Low: $3.04
High: $3.40

50 Day Range

MA: $3.38
Low: $3.01
High: $4.08

2 Week Range

Now: $3.18
Low: $2.75
High: $5.13

Volume

356,961 shs

Average Volume

140,294 shs

Market Capitalization

$101.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84